NOX - Noxopharm Limited

[Dona Ferentes]

good news helping the SP to a 2 year high .... up 10% today

Global Conference to Hear of Major Survival Benefit in Prostate Cancer Patients

• Noxopharm claims emergence of a major new treatment for prostate cancer
• LuPIN drug combination of Veyonda and 177Lu-PSMA-617 (Novartis) results in half of all patients surviving at least 19.7 months, a ground-breaking outcome for men with end-stage (Stage 4) disease and no remaining treatment options
• Data being presented to global cancer conference (11-13 February 2021)
• Noxopharm undertaking strategic discussions with respect to making LuPIN treatment a new standard of care
• Survival benefit exceeds that reported for any current standard of care treatment including one acquired by Pfizer in 2016 for US$14 billion

 

[tinhat]

Cantrixil

 

[Dona Ferentes]

Response to ASX Price Query
Noxopharm Limited (ASX: EX1) (“Noxopharm” or the “Company”) refers to your Price Query letter dated Thursday 1 September 2022 and provides the following responses:

1. The Company is not aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities.
2. The Company has no other explanation as to why there has been a price and volume change in the trading of the Company’s securities.
3. The Company confirms that it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
4. The Company confirms that this response has been authorised and approved by the Board of Directors.

Yours sincerely,
David Franks, Company Secretary

........ company secretary on top of his game! There was a correction afterwards

 

[Country Lad]

Noxopharm Limited (ASX: EX1) (“Noxopharm”

........ company secretary on top of his game! There was a correction afterwards

Not the only thing they got wrong!!

 

[Dona Ferentes]

Been a slow recovery, slow build

from 28/03:
Noxopharm Announces Novel mRNA Vaccine Enhancer
• Proprietary SOF-VACTM asset with potential to make mRNA vaccines safer, better tolerated by patients and more cost-effective to manufacture
• Preclinical first-in-class mRNA technology based on company’s SofraTM platform
• Smallest molecule of its type to have demonstrated strong activity against inflammation
• Developed in collaboration with strategic partner Hudson Institute of Medical Research
• Growing worldwide activity in multi-billion mRNA market

 

[Dona Ferentes]

Been a slow recovery, slow build

• Growing worldwide activity in multi-billion mRNA market

But not that fast. In fact, snails give good competition
a 'refocus' and down 40+%, below 6c at one point

... so the great white hope became a big black hole

 

[Dona Ferentes]

Been a slow recovery,

until...

.
bit naughty.

.
Trading halt is requested pending an announcement by the Company to the market regarding the determination of the designation by FDA for pancreatic cancer drug candidate CRO-67.

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:
- The trading halt is necessary to assist Noxopharm in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated Purpose above.

 

[Dona Ferentes]

back trading, up 150 per cent ... 15c. someone benefited more than others.
.

US FDA grants Orphan Drug Designation for CRO-67​

• US Food and Drug Administration grants Orphan Drug Designation for treatment of pancreatic cancer
• Benefits include tax credits and commercial exclusivity
• Supports company’s development plan and commercial strategy

 

[Telamelo]

back trading, up 150 per cent ... 15c. someone benefited more than others.
.

US FDA grants Orphan Drug Designation for CRO-67​

• US Food and Drug Administration grants Orphan Drug Designation for treatment of pancreatic cancer
• Benefits include tax credits and commercial exclusivity
• Supports company’s development plan and commercial strategy

Noticed that sp shot up +48% yesterday just prior to trading halt wtf!? insider trading!? surprised asx hasn't queried price action leading up to trading halt..

 

[Dona Ferentes]

Noticed that sp shot up +48% yesterday just prior to trading halt wtf!? insider trading!? surprised asx hasn't queried price action leading up to trading halt..

yep... early birds ...
after the return, initial excitement drove it up on Wed, then the usual profit taking and etc; the close by Fri was strong. so all is forgiven

 

[Dona Ferentes]

around 11c
from a few days ago
.
3. When did NOX first become aware of the Information.
As is industry standard for small biotech companies, NOX undertook its US FDA application for Orphan Drug Designation for CRO-67 through an independent outside regulatory consultant.

The Regulatory Consultant, amongst other things, assisted in completing and lodging the Application in June 2023, and is the sole method of communication between NOX and the FDA in respect of the status and outcome of the Application.

The Regulatory Consultant advised NOX of the outcome of the Application by email at 12.04pm AEDT Tuesday 3 October 2023. This is the time when the Company first became aware of the Information.

 

[Dona Ferentes]

around 11c...

NOX is out of the box. 12c

mRNA Vaccine Enhancer Shows Significant Inflammation Reduction
• New data shows SOF-VAC™ significantly reduces mRNA-driven inflammation in animal model
• Effectiveness of RNA remains high
• Comprehensive data package achieved, actively seeking commercial partner for next stage